Navigation Links
Chimerix's PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
Date:11/16/2010

rganic Anion Transporter 1 (hOAT1) and hOAT3, which are both linked to kidney excretion of endogenous substances and certain drugs.  Researchers noted that net uptake of CMX001 and CMX157 was not enhanced in OAT-expressing cells.  These data provide evidence that CMX001 and CMX157 are not substrates of human OAT1 and OAT3 and therefore have a low potential to cause OAT-mediated nephrotoxicity.  In contrast, uptake of cidofovir and tenofovir was enhanced in in vitro cells expressing OAT1, consistent with previous literature reports.  

"Nephrotoxicity is a serious and potentially life-threatening adverse effect associated with the antiviral agents cidofovir and tenofovir.  Through the application of our proprietary PIM Conjugate Technology we are able to dramatically alter drug distribution and thereby potentially avoid nephrotoxicity," said George Painter, Ph.D., Chief Scientific Officer of Chimerix.  "Our animal and clinical studies of CMX001 and CMX157, in which both compounds have demonstrated a positive safety profile, are consistent with our in vitro observations that CMX001 and CMX157 are not metabolized in the kidney.  Furthermore, these data are consistent with, and provide a mechanistic explanation for, data presented at the recent ICAAC meeting that CMX001 was well tolerated in 46 patients with compromised renal function."

Chimerix is developing CMX001 for dual-use as a broad-spectrum antiviral for the treatment of life-threatening viruses in immunocompromised transplant and cancer patients and as a medical countermeasure in the event of a smallpox release.  CMX001 is currently in Phase 2 clinical trials for the prophylaxis and treatment of human cytomegalovirus infection. CMX157 is currently in Phase 1 clinical testing for the treatment of HIV infections.

Cidofovir and tenofovir are polar, acyclic nucleoside phosphonates that are FDA-approved as Vistide® (cidofovir injection) f
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
3. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
4. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
5. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
6. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
7. The Israeli Governments Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology
8. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
9. New forms of highly efficient, flexible nanogenerator technology
10. Verenium to Present at Jefferies 10th Global Clean Technology Conference
11. Voluntary initiatives, regulation and nanotechnology oversight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)...   Epic Sciences, Inc. , a private diagnostics ... personalize and advance the treatment and management of cancer, ... under its existing credit facility with Silicon Valley ... capacity of the facility from $5 million to $15 ... to April 1, 2019.  The availability of additional capital ...
(Date:6/1/2015)... , May 29, 2015 ... the addition of the "2015 Strategies ... report to their offering. ... and provides a comprehensive analysis of the ... size, growth, regulatory requirements, technological trends, competitive ...
(Date:6/1/2015)... -- Hutchison China MediTech Limited ("Chi-Med") ... ("AstraZeneca"), Hutchison MediPharma Limited,s ("HMP") collaboration partner, presented ... trial of HMP,s c-Met inhibitor savolitinib (AZD6094) combined ... lung cancer ("NSCLC"). AZD9291 is AstraZeneca,s ... (EGFR). Preliminary data on the activity of AZD9291 ...
(Date:5/31/2015)... (PRWEB) May 31, 2015 Grow Med ... that enables growers to progress at their own pace ... white papers, efficacy reports, and both scientific and other ... help them produce their best harvest yet! , ... marijuana is the fastest-growing industry in the U.S. and ...
Breaking Biology Technology:Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 3Grow Med University: a Brand New Online Hydroponics Course 2
... Superiority Over,Market-Leading Stent in Clinical Trials, Now Available in United ... Treatment ... Abbott today,announced that the U.S. Food and Drug Administration ... the treatment of,coronary artery disease. XIENCE V is the only ...
... new products coming soon to Bioniche,s growing line of injectable ... ... Bioniche Pharma, a leading,developer and manufacturer of injectable pharmaceuticals, announced today,the ... (edrophonium chloride injection, USP) 10 mg/mL, 15 mL vial -- ENLON-PLUS(R) ...
... and Sales; Susan Koppy ... Corporate Development, PT. RICHMOND, Calif., July 2 Transcept ... position of,Vice President, Marketing and Sales and Susan Koppy to ... Ms. Koppy will report,to President & Chief Executive Officer Glenn ...
Cached Biology Technology:FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 2FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 3FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 4FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 5Bioniche Pharma Acquires Baxter's ENLON(R) and ENLON-PLUS(R) 2Transcept Pharmaceuticals Appoints Key Senior Executives 2Transcept Pharmaceuticals Appoints Key Senior Executives 3Transcept Pharmaceuticals Appoints Key Senior Executives 4
(Date:5/27/2015)... , May 27, 2015   Codonics ... safety systems and image documentation solutions and ... comprehensive, technologically-advanced automation solutions, is pleased to ... The Codonics® Safe Label System® (SLS), an ... conjunction with the Omnicell Anesthesia Workstation, helps ...
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3
... mechanism has been discovered in a microorganism that thrives in ... key processes in human cells, and in a better understanding ... study is published today in the online version the American ... group at the Department of Molecular Evolution at Uppsala University ...
... innate defence system against deadly bacteria. However, how the step ... not yet known. To date, B. Pseudomallei, a ... can remain hidden in the human body for many years ... suddenly become activated and spread throughout the body, resulting in ...
... Measures to tackle the human impact on biodiversity ... countries working with common goals and frameworks. This ... European Science Foundation (ESF), which moved towards establishing ... and biodiversity analysis on the back of existing ...
Cached Biology News:New cell division mechanism discovered 2European biodiversity and ecosystem scientists merge and gear up for long-term research 2
... FAST RED Chromogen System consists ... substrate buffer. FAST RED reacts ... phosphatase to produce red staining ... The FAST RED ...
Mouse Cell Line Slides...
Human Cell Line Slides...
... most comprehensive, cost-effective solution to your ... unprecedented quality into both our products ... detection chemistries and antibodies that have ... It also includes our competitively priced ...
Biology Products: